Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
| Status: | Completed |
|---|---|
| Conditions: | Schizophrenia, Psychiatric, Diabetes |
| Therapuetic Areas: | Endocrinology, Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 14 - 50 |
| Updated: | 4/2/2016 |
| Start Date: | August 2003 |
| End Date: | June 2014 |
| Contact: | Ripu D Jindal, MD |
| Email: | jindalr@upmc.edu |
| Phone: | 412 512 9516 |
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes
mellitus in patients with schizophrenia. As part of the study, we collect
neuroendocrine-immune data on patients with first episode, treatment naive psychosis,
patients with newly diagnosed schizophrenia and normal healthy controls.
Regardless the treatment status, we collect the same neuroendocrine-immune data on the
participants after 2 months.
mellitus in patients with schizophrenia. As part of the study, we collect
neuroendocrine-immune data on patients with first episode, treatment naive psychosis,
patients with newly diagnosed schizophrenia and normal healthy controls.
Regardless the treatment status, we collect the same neuroendocrine-immune data on the
participants after 2 months.
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes
mellitus in patients with schizophrenia. As part of the study, we collect
neuroendocrine-immune data on patients with first episode, treatment naive psychosis,
patients with newly diagnosed schizophrenia and normal healthy controls.
Regardless the treatment status, we collect the same neuroendocrine-immune on the
participants (patients and controls) after 2 months. Thus, our study does not control
treatment. Patients take treatment in consultation with their physician. Some of them even
decide not to take any medications. At the 2nd visit, we do ask them about the the
medications they are taking if any.
mellitus in patients with schizophrenia. As part of the study, we collect
neuroendocrine-immune data on patients with first episode, treatment naive psychosis,
patients with newly diagnosed schizophrenia and normal healthy controls.
Regardless the treatment status, we collect the same neuroendocrine-immune on the
participants (patients and controls) after 2 months. Thus, our study does not control
treatment. Patients take treatment in consultation with their physician. Some of them even
decide not to take any medications. At the 2nd visit, we do ask them about the the
medications they are taking if any.
Inclusion Criteria:
- Psychotic disorder as per DSM-IV criteria of the American Psychiatric Association
Exclusion Criteria:
- Diabetes, type 1 or 2
- Prominent substance abuse (i.e. psychotic symptoms attributable entirely to substance
use)
- Age above 50 or age below 14
We found this trial at
1
site
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
Click here to add this to my saved trials
